1. 1275PSafety and clinical activity of subcutaneously (SC) administered anti-PD-1 antibody PF-06801591 in phase I dose-expansion cohorts of locally advanced or metastatic non-small cell lung cancer (NSCLC) and urothelial carcinoma (UC). (1st October 2019) Authors: Cho, B C; Penkov, K; Bondarenko, I; Korozan, M; Kurochkin, A; Pikiel, J; Kulyaba, Y; Ahn, H K; Odintsova, S; Davda, J; Forgie, A; Wang, X; Li, R; Jacobs, I A; Kazazi, F; Chou, J; Johnson, M L Journal: Annals of oncology Issue: Volume 30(2019)Supplement 5 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗